LUNG

Pulmonx Corporation (NASDAQ:LUNG) is a medical technology company founded in 1995 and headquartered in Redwood City, California. The company specializes in developing and commercializing minimally invasive devices for treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Since going public in October 2020, Pulmonx has focused on expanding its flagship Zephyr Endobronchial Valve system globally while developing complementary technologies to address the broader COPD patient population.